USA flag logo/image

An Official Website of the United States Government

OUR SPECIFIC AIM IS TO SYNTHESIZE PROPRIETARY DRUGS TO TREAT SCHISTOSOMIASIS,…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
1364
Program Year/Program:
1984 / SBIR
Agency Tracking Number:
1364
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Orphan Designed Drugs Inc.
475 Rolling Hills Road Bridgewater, NJ 08807
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1984
Title: OUR SPECIFIC AIM IS TO SYNTHESIZE PROPRIETARY DRUGS TO TREAT SCHISTOSOMIASIS, LEISHMANEASIS AND TRYPANOMIASIS PARASITIC DISEASES.
Agency: HHS
Contract: N/A
Award Amount: $23,050.00
 

Abstract:

OUR SPECIFIC AIM IS TO SYNTHESIZE PROPRIETARY DRUGS TO TREAT SCHISTOSOMIASIS, LEISHMANEASIS AND TRYPANOMIASIS PARASITIC DISEASES. THE BASIS FOR THIS PROPOSAL IS RELATED TO TWO TECHNICAL ASSUMPTIONS WHICH SHOULD GREATLY REDUCE THE TOXICITY OF ANTIMONY WHILE ENHANCING THE EFFICACY OF THE DRUGS. THERE ARE SCATTERED REFERENCES FROM THE PUBLISHED LITERATURE SUGGESTING THESE IMPROVEMENTS. APPROXIMATELY 20 NEW TRIVALENT ANTIMONY COMPOUNDS WILL BE PREPARED. PRIMARILY THEY WILL BE DERIVATIVES OF CARBOXYLIC ACIDS, HYDROXY-CARBOXYLIC ACIDS AND CARBOHYDRATES. THESE NEW COMPOSITIONS WILL BE TESTED AT THE UNIVERSITY OF GEORGIA BY PROF. WILLIAM L. HANSON. BESIDES REDUCING TOXICITY, ANOTHER BADLY NEEDED IMPROVEMENT IN THE THERAPEUTIC ADMINISTRATION OF ANTIPARASITIC DRUGS WOULD BE TO HAVE THE DRUGS TAKEN ORALLY RATHER THAN BY INCONVENIENT AND PAINFUL SUBCUTANEROUS OR INTRAMUSCULAR INJECTIONS. THE STRUCTURAL MODIFICATIONS OF THIS PROPOSAL SHOULD RESULT IN MORE STABLE AND BIOAVAILABLE ANTIMONY COMPOSITIONS ADMINISTERED BY ORAL INGESTION. THE AWARD, IF GRANTED, WOULD GIVE OUR NEW FLEDGLING FIRM CREDIBILITY. SUBSEQUENTLY, IT WOULD BE EASIER TO OBTAIN ADDITIONAL CAPITAL FROM VARIOUS SOURCES SUCH AS OTHER INTERESTED FEDERAL AGENCIES, THE WORLD HEALTH ORGANIZATION OR VENTURE CAPITAL FIRMS TO ASSIST US IN BUILDING UP OUR R&D AND MANUFACTURING FACILITIES.

Principal Investigator:

Dr. j.a. hoffman
0

Business Contact:

Small Business Information at Submission:

Orphan Designed Drugs Inc.
475 Rolling Hills Road Bridgewater, NJ 08807

EIN/Tax ID:
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No